IP Library Granted Patent US 7,201,921
Granted Patent B2
US 7,201,921 · App. 10/384,868 · Granted Apr 10, 2007

Antihistamine formulations for soft capsule dosage forms

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,201,921
App. No.
10/384,868
Granted
Apr 10, 2007
Kind
B2
Abstract

The invention herein relates to a pharmaceutical composition containing loratadine and derivatives thereof which is suitable for use in soft capsule dosage forms. A pharmaceutical composition according to the invention comprises loratadine and derivatives thereof in a pharmaceutically effective amount; and a solvent system comprising a mixture of medium chain fatty acids. The loratadine compositions exhibit good solubility and storage stability while maintaining bioavailability of the drug. The compositions also permit high concentrations of solubilized loratadine per total fill volume and thereby permit the use of smaller capsules to deliver the same dosage of drug.

Claims (18)

1. A soft capsule dosage form comprising a fill composition consisting essentially of:

a) a decarbalkoxylated loratadine derivative in a pharmaceutically effective amount;

b) a mixture of mono- and diglycerides of medium chain fatty acids;

c) povidone;

d) polyoxyethylene sorbitan fatty acid ester; and

wherein said soft capsule has a capsule size of 5 minim or less to about 1 minim; and

wherein the soft capsule comprises a capsule material comprising carrageenan.

2. The soft capsule dosage form according to claim 1 wherein the decarbalkoxylated loratadine derivative is descarboethoxyloratadine.

3. The soft capsule dosage form according to claim 1 , wherein said carrageenan is iota-carrageenan.

4. The soft capsule dosage form according to claim 3 , wherein the capsule material further comprises hydroxypropyl starch.

5. The soft capsule dosage form according to claim 4 , wherein the capsule material further comprises glycerin.

6. The fast capsule dosage form according to claim 1 , wherein the capsule material comprises the following formulation:

a) iota-carrageenan;

b) hydroxypropyl starch;

c) glycerin;

d) anhydrous disodium phosphate; and

e) water.

7. The soft capsule dosage form according to claim 6 , wherein the capsule material further comprises an additive selected from the group consisting of flavoring agents, opacifying agents, preservatives, embrittlement inhibiting agents, colorants, dyes and pigments, and disintegrants.

Assignments (4)
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL (019323/0302) Recorded Dec 19, 2024
From: JPMORGAN CHASE BANK, N.A.
To: CATALENT PHARMA SOLUTIONS, LLC; R.P. SCHERER TECHNOLOGIES, INC.; R.P. SCHERER TECHNOLOGIES, LLC; R.P. SCHERER CORPORATION
Reel/Frame 069750/0933 →
NOTICE OF SUCCESSION OF AGENCY Recorded May 17, 2019
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 049217/0981 →
CHANGE OF NAME Recorded Jul 24, 2007
From: CARDINAL HEALTH 400, INC.; CARDINAL HEALTH 406, LLC; CARDINAL HEALTH 409, INC.; CARDINAL HEALTH 421, INC.; CARDINAL HEALTH PTS, LLC
To: CATALENT USA WOODSTOCK, INC.; CATALENT USA PACKAGING, LLC; CATALENT PHARMA SOLUTIONS, INC.; CATALENT USA PAINTBALL, INC.; CATALENT PHARMA SOLUTIONS, LLC
Reel/Frame 019588/0622 →
SECURITY AGREEMENT Recorded May 22, 2007
From: PTS ACQUISITION CORP.; PTS INTERMEDIATE HOLDINGS LLC; CARDINAL HEALTH 400, INC.; CARDINAL HEALTH 406, LLC; CARDINAL HEALTH 421, INC.; CARDINAL HEALTH PTS, LLC; R.P. SCHERER TECHNOLOGIES, INC.; GLACIER CORPORATION; CARDINAL HEALTH 409, INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 019323/0302 →